Portfolio Lab

Edwards Lifesciences Corp

  • Stock
  • Ticker EW
  • ISIN US28176E1082
  • NYSE

Health care · Medical technology · USA

$101.85 −1.95%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Edwards Lifesciences Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

EWGlobal equities (VT)

$10,000 grew to $34,254. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −54.3% in 07/2024, measured from the peak in 12/2021. The old peak has not been reached again yet.

1-year return
+21.1%
5-year return p.a.
−2.7%
10-year return p.a.
+13.1%
Volatility p.a.
29.4%
Largest decline
−54.3%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1,3861,4131,5321,5531,5701,6491,7411,716
Gross profit1,0941,1111,1881,2081,2271,2861,3491,346
Operating income313395411307151478513299
EBITDA355431449346194519556344
Net income38635833329191381242308
Earnings per share0.650.610.560.500.160.660.420.53
Balance sheet
Total assets13,05513,02213,48913,27213,69713,32113,86714,144
Liabilities2,9922,8312,8823,0673,3602,9943,1423,183
Equity9,99810,12910,54510,20510,33810,32810,61810,861
Cash3,0453,1413,2732,6862,9382,4462,9073,111
Long-term debt598598598598598599599599
Cash flow
Operating cash flow-12828029057445144652570
Capital expenditure-50-56-49-58-97-65-67-64
Free cash flow-177224241516354-21585507

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +52.3%, weakest 2022 at −42.4%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$0.53
4 Aug 2026$0.42
6 May 2026$0.66
25 Feb 2026$0.16
5 Nov 2025$0.50
6 Aug 2025$0.56
6 May 2025$0.61
28 Feb 2025$0.65
6 Nov 2024$5.13
31 Jul 2024$0.61
29 Apr 2024$0.58
12 Feb 2024$0.61

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€53bn
Market cap in trading currency
$58.6bn
Enterprise value
$54.5bn
P/E
57.5
P/S
8.77
P/B
5.39
EV/Sales
8.17
EV/EBITDA
33.8
Earnings yield
1.7%
FCF yield
2.4%

Results (last four quarters)

Revenue
$6.67bn
Gross profit
$5.21bn
EBITDA
$1.61bn
Net income
$1.02bn
Earnings per share
$1.77
Revenue per share
$11.61
Revenue growth
+10.5%
Earnings growth
+5.6%

Profitability

Gross margin
78.0%
Operating margin
21.6%
Net margin
15.3%
Return on equity
9.7%
Return on assets
7.2%

Balance sheet and cash flow

Cash
$4.64bn
Cash per share
$8.08
Financial debt
$599m
Debt/equity %
6
Current ratio
4.60
Book value per share
$18.89
Operating cash flow
$1.72bn
Free cash flow
$1.42bn

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
575m
Volume
3.51m
Avg. volume 3 months
3.85m
Relative volume
0.9

Price and technicals

Price
$101.85
1 day
−2.0%
52-week high
$107.15
52-week low
$75.87
Distance to 52-week high
−4.9%
Distance to 52-week low
+34.2%
Distance to 50-day line
+10.4%
Distance to 200-day line
+17.2%
RSI (14)
59
Volatility 1M
27.6%

Performance

1 week
−4.9%
1 month
+13.1%
3 months
+12.5%
6 months
+18.7%
YTD
+19.5%
1 year
+18.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has EW performed since 11/2016?

$10,000 grew to $34,254 by 20 Nov 2026, which is +13.1% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is EW?

Volatility was 29.4% per year, measured on monthly returns. The largest decline from a peak was −54.3%, with the low in 07/2024.

How does EW compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, EW returned +13.1% at 29.4%. The correlation of monthly returns was 0.45; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Edwards Lifesciences Corp (EW): Return and risk